Immunotherapies have emerged as one of the vital options for treating cancer patients. A num-ber of cancer immunotherapies are now available worldwide. To select the right immunotherapy for the right patient, updated information is the key. This presentation outlines the key information and results of five latest clinical studies on different cancer immunotherapies. The studies are selected through a search in PubMed (Keyword: ‘Cancer Immunotherapy’; Sort-ed by: ‘Most Recent’; Filter: ‘Clinical Trial’ and ‘Publication time 1 year’). Only randomized controlled studies are included here. These studies have revealed that immunotherapies ensure encouraging outcomes not only in enhancing the quality of life but also in boosting the overall survival rate of cancer patients.

1. SHAUKET HOSSAIN
Deputy General Manager, Marketing
UniHealth Limited, Bangladesh
Latest Studies in
Cancer Immunotherapy

2. Agenda
 Brief idea on cancer immunotherapies
 Update on currently available cancer immunotherapies and their
approved indications
 Outline of key information and results of five latest clinical
studies on different cancer immunotherapies

3. Birth of cancer immunotherapy
Ref. Immunotargets Ther. 2018 Apr 23;7:29-34.
 Dr. William Bradley Coley
Has been regarded as the
founder of cancer
immunotherapy for his
legendary discovery of
‘Erysipelas Germs as Cure
for Cancer’ in 1908.

4. Cancer immunotherapy
Ref. Int J Cardiol. 2021 Jan 15;323:179-187.
 Immunotherapy is a type of targeted
cancer treatment that helps our immune
system to fight cancer.
 It is a biological therapy made from living
organisms or cells.
 It helps the immune system to fight
against cancer in a better way.
 The goal of immunotherapy is to achieve
durable tumor regression & possible cure
with minimum adverse effects on patients.

5. MABs for Cancer Treatment
 Atezolizumab
 Durvalumab
 Avelumab
 Ipilimumab
 Nivolumab
 Cemiplimab
 Dostarlimab
 Pembrolizumab
 Tafasitamab
 Loncastuximab
 Blinatumomab
 Rituximab
 Obinutuzumab
 Ofatumumab
 Mosunetuzumab
 Inotuzumab
 Isatuximab
 Daratumumab
 Polatuzumab
 Belantamab
 Brentuximab
 Mogamulizumab
 Bevacizumab
 Ramucirumab
 Cetuximab
 Panitumumab
 Amivantamab
 Trastuzumab
 Margetuximab
 Sacituzumab
 Gemtuzumab
 Dinutuximab

6. Ref. Int J Mol Sci. 2022 Nov 23;23(23):14589.
MABs for Cancer Treatment
MAB Approved Indication
Atezolizumab Non-Small Cell Lung Cancer; Extensive-Stage Small Cell Lung Cancer; Unresectable or
Metastatic Hepatocellular Carcinoma; Unresectable or Metastatic Melanoma
Durvalumab Non-Small Cell Lung Cancer; Extensive-Stage Small Cell Lung Cancer; Unresectable or
Metastatic Hepatocellular Carcinoma; Locally Advanced or Metastatic Biliary Tract Cancer
Avelumab Metastatic Merkel Cell Carcinoma; Urothelial Carcinoma
Ipilimumab Metastatic Melanoma; Advanced Renal Cell Carcinoma; Non-Small Cell Lung Cancer;
Colorectal Carcinoma

7. MABs for Cancer Treatment
MAB Approved Indication
Nivolumab Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Small Cell Lung Cancer;
Advanced Renal Cell Carcinoma; Classical Hodgkin Lymphoma; Squamous Cell Carcinoma
of Head & Neck; Urothelial Carcinoma; Metastatic Colorectal Cancer; Hepatocellular
Carcinoma
Cemiplimab Metastatic Cutaneous Squamous Cell Carcinoma; Locally Advanced Cutaneous Squamous
Cell Carcinoma; Non-small Cell Lung Cancer
Dostarlimab Advanced Endometrial Cancer
Pembrolizumab Advanced Melanoma; Advanced Non⁠–⁠Small Cell Lung Cancer; Relapsed or Refractory
Classical Hodgkin Lymphoma; Refractory or Relapsed Mediastinal Large B-cell Lymphoma;
Advanced Urothelial Carcinoma; High-Risk Non-muscle Invasive Bladder Cancer; High-Risk
Risk Early-Stage Triple-Negative Breast Cancer

8. Ref. Int J Mol Sci. 2022 Nov 23;23(23):14589.
MABs for Cancer Treatment
MAB Approved Indication
Tafasitamab Refractory Diffuse Large B-cell Lymphoma
Loncastuximab Relapsed or Refractory Large B-cell Lymphoma
Blinatumomab B-precursor Acute Lymphoblastic Leukemia
Rituximab Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Obinutuzumab Chronic Lymphocytic Leukemia; Follicular Lymphoma

9. Ref. Int J Mol Sci. 2022 Nov 23;23(23):14589.
MABs for Cancer Treatment
MAB Approved Indication
Ofatumumab Relapsing forms of Multiple Sclerosis
Mosunetuzumab Relapsed or Refractory Follicular Lymphoma
Inotuzumab Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Isatuximab Multiple Myeloma
Daratumumab Multiple Myeloma

10. Ref. Int J Mol Sci. 2022 Nov 23;23(23):14589.
MABs for Cancer Treatment
MAB Approved Indication
Polatuzumab Relapsed or Refractory Diffuse Large B-cell Lymphoma
Belantamab Multiple Myeloma
Brentuximab Hodgkin Lymphoma; Systemic Anaplastic Large Cell Lymphoma
Mogamulizumab Relapsed or Refractory Mycosis Fungoides
Bevacizumab Metastatic Colorectal Cancer; Non-Squamous Non–Small Cell Lung Cancer;
Metastatic Renal Cell Carcinoma

11. Ref. Int J Mol Sci. 2022 Nov 23;23(23):14589.
MABs for Cancer Treatment
MAB Approved Indication
Trastuzumab Adjuvant Breast Cancer; Metastatic Breast Cancer; Metastatic Gastric Cancer
Sacituzumab Metastatic Triple-negative Breast Cancer
Gemtuzumab Newly-Diagnosed CD33-positive Acute Myeloid Leukemia; Relapsed or
Refractory CD33-positive AML
Dinutuximab Pediatric Patients with High-risk Neuroblastoma

12. Latest Studies in
Cancer Immunotherapy

13. Methodology
 This presentation outlines the key information and results of five latest
clinical studies on different cancer immunotherapies.
 The studies are selected through a search in PubMed (Keyword: ‘Cancer
Immunotherapy’; Sorted by: ‘Most Recent’; Filter: ‘Clinical Trial’ and
‘Publication time 1 year’).
 Only randomized controlled studies are included here.

14. KEYNOTE-716 Study
 Double-blind, randomized, placebo-controlled, Phase-3 study
 160 academic medical centers & hospitals in 16 countries
(Australia, Belgium, Brazil, Canada, Chile, France, Germany, Israel,
Italy, Japan, Poland, South Africa, Spain, Switzerland, UK & USA)
 976 patients with stage IIB or IIC melanoma who underwent
surgery were enrolled
 Patients received either 200 mg pembrolizumab (n=487) of or
saline placebo (n=489) intravenously every 3 weeks for 17 cycles
 Median follow-up: 27.4 months
Ref. Lancet. 2022 Apr 30;399(10336):1718-1729.

15. KEYNOTE-716 Study
Ref. Lancet. 2022 Apr 30;399(10336):1718-1729.
 Pembrolizumab as
adjuvant therapy in
stage IIB or IIC
melanoma patients
resulted in a significant
reduction in the risk of
disease recurrence or
death versus placebo,
with a manageable
safety profile

16. KEYNOTE-564 Study
 Double-blind, randomized, placebo-controlled, Phase-3 study
 213 hospitals & cancer centers in North America, South America,
Europe, Asia, and Australia
 994 patients with renal cell carcinoma with an increased risk of
recurrence were enrolled
 Patients received either 200 mg (n=496) of or saline placebo
(n=498) intravenously every 3 weeks for 17 cycles
 Median follow-up: 30.1 months
Ref. Lancet Oncol. 2022 Sep;23(9):1133-1144.

17. KEYNOTE-564 Study
 Disease-free
survival was better
with
pembrolizumab
compared with
placebo
Ref. Lancet Oncol. 2022 Sep;23(9):1133-1144.
HR 0.63 [95% CI 0.50-0.80]

18. ORIENT-11 Study
 Double-blind, randomized, placebo-controlled, Phase-3 study
 Conducted in Chinese participants from mainland China
 397 patients with treatment-naïve advanced metastatic non-
squamous NSCLC were enrolled
 Patients received either Sintilimab + Pemetrexed-Platinum
(n=266) or Placebo + Pemetrexed-Platinum (n=131)
 Median follow-up: 30.8 months
Ref. Lung Cancer. 2022 Sep;171:56-60.

19. ORIENT-11 Study
Ref. Lung Cancer. 2022 Sep;171:56-60.
 Median OS (Overall
Survival) was 24.2
months in
Sintilimab arm &
16.8 months in
placebo arm
 OS was better in
Sintilimab arm
(HR:0.65, 95 % CI,
0.50-0.85).

20. ORIENT-31 Study
 Double-blind, randomized, placebo-controlled, Phase-3 study
 Conducted at 52 hospitals in China
 444 patients with locally advanced or metastatic EGFR-mutated
NSCLC were enrolled
 Patients received either Sintilimab + Bevacizumab +
Chemotherapy (n=148) or Sintilimab + Chemotherapy (n=145) or
Chemotherapy alone (n=151)
 Median follow-up: 9.8 months
Ref. Lancet Oncol. 2022 Sep;23(9):1167-1179.

21. ORIENT-31 Study
Ref. Lancet Oncol. 2022 Sep;23(9):1167-1179.
 Progression-free
survival was
significantly longer in
Sintilimab +
Bevacizumab +
Chemotherapy group
versus Chemotherapy
alone group (HR 0.46,
0.34-0.64; p<0.0001).

22. CAPSTONE-1 Study
 Double-blind, randomized, placebo-controlled, Phase-3 study
 Conducted at 47 tertiary hospitals in China
 462 patients with extensive-stage small-cell lung cancer were
enrolled
 Patients received either Adebrelimab + Chemotherapy (n=230) or
Placebo + Chemotherapy (n=232)
 Median follow-up: 13.5 months
Ref. Lancet Oncol. 2022 Sep;23(9):1167-1179.

23. CAPSTONE-1 Study
Ref. Lancet Oncol. 2022 Sep;23(9):1167-1179.
 Median overall
survival was
significantly
improved in the
Adebrelimab group
(HR 0.72, 95% CI,
0.58-0.90;
p=0.0017)

24. Summary
# Study Patient’s Information Treatment Protocol Key Result
1. KEYNOTE-716 976 patients with stage IIB
or IIC melanoma who
underwent surgery
Pembrolizumab (n=487) or Placebo (n=489)
Median follow-up: 27·4 months
 Pembrolizumab significantly improved
metastasis-free survival (HR 0·64, 95% CI,
0·47-0·88; p=0·0029) versus placebo.
2. KEYNOTE-564 994 patients with clear cell
RCC who underwent
surgery
Pembrolizumab (n=496) or Placebo (n=498)
Median follow-up: 30.1 months
 Disease-free survival was better with
pembrolizumab (HR 0·63, 95% CI, 0·50-0·80).
3. ORIENT-11 397 patients with treatment-
naïve advanced metastatic
nonsquamous NSCLC
Sintilimab + Pemetrexed-Platinum (n=266) or
Placebo + Pemetrexed-Platinum (n=131)
Median follow-up: 30.8 months
 Overall survival was better in Sintilimab arm
(HR:0.65, 95 % CI, 0.50-0.85).
4. ORIENT-31 444 patients with locally
advanced or metastatic
EGFR-mutated NSCLC
Sintilimab + Bevacizumab + Chemotherapy
(n=148) or Sintilimab + Chemotherapy
(n=145) or Chemotherapy alone (n=151)
Median follow-up: 9.8 months
 Progression-free survival was significantly
longer in the Sintilimab + Bevacizumab +
Chemotherapy group versus the Chemotherapy
alone group (HR 0·46, 0·34-0·64; p<0·0001).
5. CAPSTONE-1 462 patients with extensive-
stage small-cell lung cancer
Adebrelimab + Chemotherapy (n=230) or
Placebo + Chemotherapy (n=232)
Median follow-up: 13·5 months
 Median overall survival was significantly
improved in the Adebrelimab group (HR 0·72,
95% CI, 0·58-0·90; p=0·0017)

25. THANKS!